Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in advanced melanoma (ADAPTeM)
NCT02663258Phase 2Withdrawn
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Jan 2016
- Primary completion
- Jul 2017
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of pembrolizumab in melanoma, sponsored by Royal Marsden NHS Foundation Trust. Planned start Jan 2016; status: withdrawn.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02663258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02663258.